Pudexacianinium (ASP5354) chloride for ureter visualization in participants undergoing laparoscopic, minimally invasive colorectal surgery.

Of 19 individuals who enrolled, six were excluded at screening and one did not receive pudexacianinium (Supplemental Fig. 1). The 12 remaining participants received 0.3 mg ( n  = 3), 1.0 mg ( n  = 6), or 3.0 mg ( n  = 3) pudexacianinium and were included in the analysis. After the first nine participants (three participants at each dose) had completed the study, the study investigators and sponsor decided to enroll three additional participants at the 1.0-mg dose of pudexacianinium to further assess ureter visualization. All three participants had BMI ≥ 25 kg/m 2 . No participants with eGFR ≥ 15 and < 60 mL/min/1.73 m 2 were enrolled in the study. In the total study population ( n  = 12), most participants were female ( n  = 10; 83.3%) and most were White ( n  = 10; 83.3%); median age was 54 years (range, 24–69 years) and median BMI was 29.3 kg/m 2 (range 18.7–38.1) (Table 1 ). Surgical procedures included total colectomy ( n  = 2), right hemicolectomy ( n  = 4), proctocolectomy ( n  = 1), lower anterior resection ( n  = 1), sigmoid resection/lower anterior resection ( n  = 2), rectosigmoid/lower anterior resection ( n  = 1), and appendectomy ( n  = 1). Surgeries ranged in duration from 59 to 186 min. Table 1 Participant demographics Pudexacianinium Total ( N  = 12) 0.3 mg ( n  = 3) 1.0 mg ( n  = 6) 3.0 mg ( n  = 3) Age, years, median (min, max) 55 (53, 58) 57 (46, 69) 45 (24, 46) 54 (24, 69) Female, n (%) 3 (100) 5 (83.3) 2 (66.7) 10 (83.3) Race, n (%)  White 2 (66.7) 5 (83.3) 3 (100) 10 (83.3)  Black or African American 1 (33.3) 0 0 1 (8.3)  Asian 0 1 (16.7) 0 1 (8.3) Ethnicity, n (%)  Hispanic or Latino, n (%) 1 (33.3) 2 (33.3) 1 (33.3) 4 (33.3) Weight, mean (SD) kg 68.2 (21.8) 83.7 (11.9) 68.4 (20.4) 76.0 (17.1) BMI, kg/m 2  Mean (SD) kg/m 2 26.7 (10.0) 29.4 (3.7) 26.8 (7.1) 28.1 (6.0)  Median 22.6 29.5 29.5 29.3  Min, max 19.4, 38.1 25.1, 34.3 18.7, 32.1 18.7, 38.1 BMI body mass index, SD standard deviation Participant demographics BMI body mass index, SD standard deviation All three doses of pudexacianinium provided enhanced anatomical visualization of ureters. Sample images of visualization during surgery from each dose group are presented in Fig.  1 . In the primary endpoint analysis, successful visualization of the index ureter at both 30 min after dosing and at the end of surgery was observed in 2/3 (66.7%), 5/6 (83.3%), and 3/3 (100%) participants in the 0.3-mg, 1.0-mg, and 3.0-mg dose groups, respectively (Table 2 ). The median fluorescence intensity values based on investigator assessment were 1 (mild) in the 0.3-mg dose group, 2 (moderate) in the 1.0-mg dose group, and 3 (strong) in the 3.0-mg dose group (Fig.  2 ). The median (range) CEF factor with dye and without dye was 1.77 (1.3–3.0) and 1.05 (0.9–1.3), respectively, for the 0.3-mg dose, 2.28 (1.3–5.6) and 1.06 (0.8–1.4), respectively, for the 1.0-mg dose, and 2.64 (1.2–7.7) and 1.10 (0.7–1.2), respectively, for the 3.0-mg dose (Fig.  3 a, b and Table 3 ). All data points under “without dye” conditions showed CEF values of approximately 1.0. As CEF values were typically greater than 1.5 with dye, the threshold for dye identification was set at this value. A correlation was observed between the surgeon’s qualitative assessment of fluorescence intensity (the surgeon’s ability to recognize/identify the ureter during surgery) and the quantitative assessment of fluorescence intensity (assessed using video recordings of the surgeries after study completion) (Fig.  3 c). Most data points of ureter visualization for patients in the 1.0-mg (89.7%) and 3.0-mg (95.2%) dose groups had CEF values above the threshold (Fig.  4 ). Fig. 1 Ureter visualizations for individual participants by dose at 30 min after pudexacianinium administration and the end of surgery Table 2 Index and contralateral ureter visualization from 10 min after pudexacianinium administration through the end of the surgical procedure n / N a (%) Index ureter Contralateral ureter 0.3 mg ( n  = 3) 1.0 mg ( n  = 6) 3.0 mg ( n  = 3) 0.3 mg ( n  = 3) 1.0 mg ( n  = 6) 3.0 mg ( n  = 3) Successful visualization b 2/3 (66.7) 5/6 (83.3) 3/3 (100) 2/3 (66.7) 2/4 (50.0) 1/2 c (50.0) Positive visualization by time point  10 min 3/3 (100) 5/6 (83.3) 3/3 (100) 2/2 (100) 1/3 (33.3) 1/1 (100)  20 min 3/3 (100) 5/6 (83.3) 3/3 (100) 2/2 (100) 2/2 (100) 1/1 (100)  30 min 3/3 (100) 5/5 (100) 3/3 (100) 2/2 (100) 2/3 (66.7) 1/1 (100)  45 min 2/2 (100) 4/4 (100) 3/3 (100) 1/1 (100) 3/3 (100) 1/1 (100)  60 min 1/1 (100) 2/2 (100) 3/3 (100) 2/2 (100) 2/2 (100) 2/2 (100)  90 min 1/1 (100) 1/1 (100) 3/3 (100) 1/1 (100) 0/0 2/2 (100)  End of surgery 2/3 (66.7) 5/6 (83.3) 3/3 (100) 2/3 (66.7) 4/4 (100) 2/2 (100) a N is the number of participants with nonmissing anatomical visualization assessments at the respective analysis time point. Missing values were considered visualization failures b Defined as positive anatomical visualization of the index ureter both 30 min after pudexacianinium dosing and at the end of surgery. Percentages are based on the nonmissing assessments at the respective time point and were counted as nonsuccess if values were missing at either time point c One patient was counted as having “nonsuccessful visualization” because of the missing assessment for the contralateral ureter at the 30-min time point Fig. 2 Fluorescence intensity of the index ureter at each time point during surgery Fig. 3 Distribution of CEF a with dye, or b without dye. c Correlation between the qualitative and quantitative assessment of fluorescent intensity. This figure shows a correlation between the qualitative assessment of fluorescence intensity determined by the surgeon and the quantitative assessment determined using video records by Stryker colleagues. Dots show observations in each dose. The lower and upper hinges correspond to the first and third quartiles (25th and 75th percentiles). The upper whisker extends from upper hinge to 1.5 × IQR. The lower whisker extends from lower hinge to 1.5 × IQR. Grey dots show outliers (data beyond the end of the whiskers). The red line illustrates the CEF threshold (1.5). CEF, contrast enhancement factor; IQR, interquartile range Table 3 Detailed index ureter visualization and quantitative results Pudexacianinium dose Participants Surgery type Index ureter Duration of surgery (minutes) Duration of visualization (minutes) a Ureter visualized Intensity score b Mean (SD)/Median (Range) CEF c Sex Age (y) BMI (kg/m 2 ) 30 min End 30 min End With dye Without dye 0.3 mg F 53 22.6 Total colectomy R 147 89 Yes No 1 0 1.84 (0.46)/1.77 (1.3–3.0) 1.10 (0.13)/1.05 (0.9–1.3) F 58 19.4 Hemicolectomy (R) R 92 61 Yes Yes 2 1 F 55 38.1 Hemicolectomy (R) R 112 52 Yes Yes 1 1 1.0 mg F 55 29.9 Lower anterior resection L 134 85 Yes Yes 2 2 2.55 (0.95)/2.28 (1.3–5.6) 1.06 (0.12)/1.06 (0.8–1.4) M 46 25.6 Sigmoid resection/lower anterior resection L 110 64 Yes Yes 2 2 F 69 32.5 Hemicolectomy (R) R 139 76 Yes Yes 3 3 F 62 29.1 Sigmoid resection/lower anterior resection L 154 44 Yes Yes 3 3 F 59 25.1 Rectosigmoid/lower anterior resection L 122 66 Yes No 3 0 F 51 34.3 Appendectomy R 59 23 Yes d Yes ND e 2 3.0 mg F 46 32.1 Hemicolectomy (R) R 130 91 Yes Yes 3 3 3.23 (1.70)/2.64 (1.2–7.7) 1.09 (0.10)/1.10 (0.7–1.2) M 45 29.5 Proctocolectomy L 186 112 Yes Yes 3 3 F 24 18.7 Total colectomy R 185 92 Yes Yes 3 3 BMI body mass index, CEF contrast enhancement factor, F female, L left, M male, ND not done, R right, SD standard deviation a Duration of visualization is defined as the last actual time of visualization minus the first actual time of visualization plus 1 min b 0 = none; 1 = mild; 2 = moderate; 3 = strong c As some color contrast between the ureter and the surrounding tissue may exist naturally, the degree to which this contrast is enhanced by the presence of the dye in the ureter may be quantified by additionally calculating a ratio defined as CEF = (G/(R + B) inside )/(G/(R + B) outside ) d Ureter visualization at 30 min is an imputed value as the 30 min time point also represents the end of surgery time point e Intensity at the 30 min time point was not performed as the 30 min time point also represents the end of surgery time point Fig. 4 Proportion of data points at each pudexacianinium dose with a CEF above threshold (1.5). The figure shows the number of observations above CEF ˃1.5/total number of observations. Proportions and 95% CIs are presented. CEF, contrast enhancement factor; CI, confidence interval Ureter visualizations for individual participants by dose at 30 min after pudexacianinium administration and the end of surgery Index and contralateral ureter visualization from 10 min after pudexacianinium administration through the end of the surgical procedure a N is the number of participants with nonmissing anatomical visualization assessments at the respective analysis time point. Missing values were considered visualization failures b Defined as positive anatomical visualization of the index ureter both 30 min after pudexacianinium dosing and at the end of surgery. Percentages are based on the nonmissing assessments at the respective time point and were counted as nonsuccess if values were missing at either time point c One patient was counted as having “nonsuccessful visualization” because of the missing assessment for the contralateral ureter at the 30-min time point Fluorescence intensity of the index ureter at each time point during surgery Distribution of CEF a with dye, or b without dye. c Correlation between the qualitative and quantitative assessment of fluorescent intensity. This figure shows a correlation between the qualitative assessment of fluorescence intensity determined by the surgeon and the quantitative assessment determined using video records by Stryker colleagues. Dots show observations in each dose. The lower and upper hinges correspond to the first and third quartiles (25th and 75th percentiles). The upper whisker extends from upper hinge to 1.5 × IQR. The lower whisker extends from lower hinge to 1.5 × IQR. Grey dots show outliers (data beyond the end of the whiskers). The red line illustrates the CEF threshold (1.5). CEF, contrast enhancement factor; IQR, interquartile range Detailed index ureter visualization and quantitative results BMI body mass index, CEF contrast enhancement factor, F female, L left, M male, ND not done, R right, SD standard deviation a Duration of visualization is defined as the last actual time of visualization minus the first actual time of visualization plus 1 min b 0 = none; 1 = mild; 2 = moderate; 3 = strong c As some color contrast between the ureter and the surrounding tissue may exist naturally, the degree to which this contrast is enhanced by the presence of the dye in the ureter may be quantified by additionally calculating a ratio defined as CEF = (G/(R + B) inside )/(G/(R + B) outside ) d Ureter visualization at 30 min is an imputed value as the 30 min time point also represents the end of surgery time point e Intensity at the 30 min time point was not performed as the 30 min time point also represents the end of surgery time point Proportion of data points at each pudexacianinium dose with a CEF above threshold (1.5). The figure shows the number of observations above CEF ˃1.5/total number of observations. Proportions and 95% CIs are presented. CEF, contrast enhancement factor; CI, confidence interval In the exploratory analysis of the benefits of visualization by pudexacianinium during surgery, consensus was achieved on all questions, suggesting clinical benefit in both the 1.0-mg and 3.0-mg dose groups (Table 4 ). Of note, according to investigators, visualization of the index ureter at the end of surgery in the 0.3-mg dose group was not possible with white light in two (66.7%) participants and NIR-F was not considered superior to white light for visualizing the index ureter in one (33.3%) participant (Table 4 ). Table 4 Clinical benefits of visualization by pudexacianinium during surgery n answering “yes,” (%) Pudexacianinium 0.3 mg ( n  = 3) 1.0 mg ( n  = 6) 3.0 mg ( n  = 3) The location of the index ureter was as expected 3 (100) 6 (100) 3 (100) Visualization of the index ureter occurred with white light 30 min after pudexacianinium administration 3 (100) 6 (100) 3 (100) Visualization of the index ureter occurred with white light at the end of surgery 1 (33.3) 6 (100) 3 (100) NIR-F was superior to white light in terms of visualization of the index ureter 2 (66.7) 6 (100) 3 (100) The location of the ureter visualized by NIR-F did not alter the operative plan 3 (100) 6 (100) 3 (100) No ureter anomalies or abnormalities were observed 3 (100) 6 (100) 3 (100) NIR-F near-infrared fluorescence Clinical benefits of visualization by pudexacianinium during surgery NIR-F near-infrared fluorescence A total of six participants experienced AEs, one of which was considered related to treatment (proteinuria grade 1, 1.0-mg dose group, resolved after 11 days, based on results of repeated urinalysis) (Table  5 ). The participant with grade 1 treatment-related proteinuria had baseline, postoperative, and follow-up creatinine levels of 79.6, 88.4, and 79.6 µmol/L, respectively; eGFR was ≥ 60 mL/min/1.73m 2 at each time point. Two (22.2%) participants experienced serious AEs, one of whom experienced perforation of the rectal stump for which histology was positive for colon cancer (coded as rectal perforation and colon cancer). The other participant experienced blood loss anemia. No serious AEs were considered drug related, and no deaths occurred during the study. Table 5 Safety summary n (%) Pudexacianinium 0.3 mg ( n  = 3) 1.0 mg ( n  = 6) 3.0 mg ( n  = 3) Total ( N  = 12) AE 2 (66.7) 5 (50.0) 1 (33.3) 6 (50.0) Drug-related AE 0 1 (16.7) 0 1 (8.3) Serious AE 2 (66.7) 0 0 2 (16.7) Worst grade ≥ 3 AE 2 (66.7) 0 0 2 (16.7) Deaths 0 0 0 0 AEs by organ class  Blood and lymphatic system disorders, n (%) 1 (33.3) 0 0 1 (8.3)    Blood loss anemia a 1 (33.3) 0 0 1 (8.3)  Gastrointestinal disorders, n (%) 1 (33.3) 0 1 (33.3) 2 (16.7)    Abdominal rigidity 0 0 1 (33.3) 1 (8.3)    Rectal perforation a 1 (33.3) 0 0 1 (8.3)  Injury, poisoning, procedural complications, n (%) 0 2 (33.3) 0 2 (16.7)    Incision site erythema 0 1 (16.7) 0 1 (8.3)    Procedural nausea 0 1 (16.7) 0 1 (8.3)    Procedural pain 0 1 (16.7) 0 1 (8.3)  Musculoskeletal and connective tissue disorders, n (%) 1 (33.3) 0 0 1 (8.3)    Muscle spasms 1 (33.3) 0 0 1 (8.3)  Neoplasms benign, malignant, and unspecified, n (%) 1 (33.3) 0 0 1 (8.3)    Colon cancer a 1 (33.3) 0 0 1 (8.3)  Renal and urinary disorders    Hematuria 0 1 (16.7) 0 1 (8.3)    Proteinuria 0 1 (16.7) 0 1 (8.3) Drug-related AE  Proteinuria 0 1 (16.7) 0 1 (8.3) AE adverse event a Serious AE unrelated to treatment Safety summary AE adverse event a Serious AE unrelated to treatment Changes from baseline in QTcF were observed in all participants during the postoperative period. Change was between 30 and 60 ms for all participants ( n  = 3) who received the 0.3-mg dose and ≤ 30 ms for all participants ( n  = 3) who received the 3.0-mg dose; change was between 30 and 60 ms for half ( n  = 3) and ≤ 30 ms for half ( n  = 3) of participants who received the 1.0-mg dose (Table 6 ). During the follow-up period, QTcF values reverted back to baseline (change ≤ 0 ms) for eight (66.7%) participants, while the remaining four (33.3%) participants experienced changes of ≤ 30 ms. Table 6 Change from baseline in QTcF by analysis visit n (%) Pudexacianinium 0.3 mg ( n  = 3) 1.0 mg ( n  = 6) 3.0 mg ( n  = 3) Total ( N  = 12) Postoperative   ≤ 0 ms 0 0 0 0   > 0 to ≤ 30 ms 0 3 (50.0) 3 (100) 6 (50.0)   > 30 to ≤ 60 ms 3 (100) 3 (50.0) 0 6 (50.0)   > 60 ms 0 0 0 0 Follow-up   ≤ 0 ms 1 (33.3) 5 (83.3) 2 (66.7) 8 (66.7)   > 0 to ≤ 30 ms 2 (66.7) 1 (16.7) 1 (33.3) 4 (33.3)   > 30 to ≤ 60 ms 0 0 0 0   > 60 ms 0 0 0 0 Any postbaseline time point   ≤ 0 ms 0 0 0 0   > 0 to ≤ 30 ms 0 3 (50.0) 3 (100.0) 6 (50.0)   > 30 to ≤ 60 ms 3 (100) 3 (50.0) 0 6 (50.0)   > 60 ms 0 0 0 0 QTcF QT interval with Fridericia’s correction Change from baseline in QTcF by analysis visit QTcF QT interval with Fridericia’s correction Plasma pudexacianinium concentrations were dose-dependent, but slightly less than dose-proportional (Table 7 ). The mean (± SD) percentage of drug dose excreted into urine during surgery was 22.3% ± 8.0% with the 0.3-mg dose, 15.6% ± 10.0% with the 1.0-mg dose, and 39.5% ± 12.4% with the 3.0-mg dose of pudexacianinium. Table 7 Pudexacianinium plasma concentration over time and total urine excretion during surgery Time 0.3 mg ( n  = 3) 1.0 mg ( n  = 6) 3.0 mg ( n  = 3) Plasma concentration, ng/mL, mean (SD)  Predose 0 (0) 0 (0) 0 (0)  10 min 48.9 (20.6) 234 (207) 322 (177)  30 min 22.5 (3.3) 67.2 (15.5) 146 (46.1)  60 min 15.3 (N/A) a 38.2 (7.4) b 106 (N/A) a  90 min 12.7 (N/A) a 34.4 (N/A) a NR  120 min 8.4 (N/A) a NR NR  End of surgery 14.0 (6.0) 39.5 (15.7) 47.3 (29.8) b  180 min NR 29.8 (16.6) a NR Pudexacianinium excreted in urine, mean (SD)  mg 0.067 (0.024) 0.156 (0.100) 1.19 (0.37)  % 22.3 (8.0) 15.6 (10.0) 39.5 (12.4) Urine collection interval, min  Mean (SD) 113.0 (27.0) 87.0 (27.0) 142.0 (35.0)  Median (range) 106 (91–143) 93 (30–115) 157 (102–168) N/A not applicable, NR not reported ( n  = 0), SD standard deviation a n  = 1 b n  = 2 Pudexacianinium plasma concentration over time and total urine excretion during surgery N/A not applicable, NR not reported ( n  = 0), SD standard deviation a n  = 1 b n  = 2

This was a phase 2, randomized, open-label, dose-ranging clinical trial in adult participants undergoing laparoscopic, minimally invasive colorectal surgery in which the surgeon expected to encounter the ureter in the operative field. This study began on October 15, 2020 at two sites in the United States in accordance with the International Council for Harmonisation guidelines, applicable regulations and guidelines governing study conduct, and the ethical principles with their origin in the Declaration of Helsinki. An institutional review board/independent ethics committee approved the ethical, scientific, and medical appropriateness of the study and reviewed the protocol (and any amendments), written informed consent, and all other documentation prior to study initiation. Participants were randomly assigned by an interactive response technology system to receive a single dose of pudexacianinium (0.3 mg, 1.0 mg, or 3.0 mg) administered as an IV injection. The investigator defined the left or right ureter as the index ureter to be evaluated for anatomical visualization with a Stryker 1688 Advanced Imaging Modalities 4 K Platform (Stryker Corporation, Kalamazoo, MI) during surgery. Dose ranges were selected using pharmacokinetic (PK) modeling and simulation to provide differentiation around a central dose of 1.0 mg based on both nonclinical findings showing that a 0.01 mg/kg dose provided sufficient ureter visualization 3 h after IV administration [ 14 ] and on PK and tolerability results in healthy volunteers [ 15 ]. Investigator(s) and the sponsor’s medical and safety representatives met after three participants completed the surgical procedures at each dose level to determine whether to expand a dose under evaluation (up to 15 participants) or discontinue a dose under evaluation. The decision to expand or discontinue a dose was based on the totality of the collected data, including, but not limited to, anatomical visualization (defined as positive visualization of the ureter at both 30 min after dose administration and at the end of surgery) or fluorescence intensity based on a Likert scale (0 = none, 1 = mild, 2 = moderate, and 3 = strong). Eligible participants were aged ≥ 18 years and scheduled to undergo laparoscopic, minimally invasive colorectal surgery during which ureters needed to be visualized. Participants were required to have adequate liver, renal, and bone marrow function. Exclusion criteria included a history of known retroperitoneal fibrosis, active urinary tract infection, previous exposure to pudexacianinium, and hypersensitivity to pudexacianinium or ICG. Participants were not permitted to have received diuretics, renal transporter inhibitors, or other NIR-F imaging agents, or to have consumed alcohol within 48 h of the study. Additional exclusion criteria included moderate to severe cardiac disease (New York Heart Association Class III-IV), mean resting heart rate of ≤ 45 or ≥ 115 bpm, mean systolic or diastolic blood pressure of ≥ 160 mmHg or ≥ 100 mmHg, respectively, mean corrected QT interval using Fridericia’s formula (QTcF) > 430 ms (male) or > 450 ms (female), or if a requirement for ureteral stenting was anticipated during surgery. Participants enrolled after determination of the selected dose were permitted to have a body mass index (BMI) > 25 kg/m 2 or an estimated glomerular filtration rate (eGFR) of ≥ 15 and < 60 mL/min/1.73 m 2 to collect information on visualization in individuals with high BMI and/or renal impairment. All participants provided written informed consent. The primary objective was to select the dose of pudexacianinium for ureter visualization in participants undergoing laparoscopic/minimally invasive colorectal surgery. The primary efficacy endpoint was successful anatomical visualization of the index ureter, defined as answering “yes” to the question “Can the ureter be adequately visualized with NIR-F?” at both 30 min after dosing and at the end of surgery. If the answer was “no” at either time point, visualization was deemed unsuccessful for that participant. Secondary objectives were to investigate the safety, tolerability, and PK of pudexacianinium; corresponding secondary endpoints included adverse events (AEs), 12-lead electrocardiogram data, pudexacianinium plasma concentrations, and urinary pudexacianinium concentration during surgery. Exploratory objectives were to investigate the relationship between the PK and pharmacodynamics of pudexacianinium, the fluorescence intensity of pudexacianinium, the duration of ureter visualization, and the benefit of visualization using pudexacianinium during surgery. Exploratory endpoints were visualization of the contralateral ureter when amenable to visualization and qualitative assessments (using a 4-point Likert scale) of fluorescence intensity and signal-to-background ratio. Efficacy endpoints were based on intraoperative ureter fluorescence visualization of the surgical field elicited using an NIR-F imaging system (FDA 510[k] cleared Stryker 1688 AIM system) positioned to visualize the index ureter. After pudexacianinium was administered, surgery was initiated and ureter visualization was assessed at time points of 10, 20, 30, 45, and 60 min, then every 30 min thereafter, and/or until the last time point before removal of visualization instruments at the end of surgery. At the investigator’s discretion, the contralateral ureter could be visualized at similar time points when feasible. Video images were captured in bright-field (white light), NIR-F, and overlay modes and recorded during the entire surgery. Anatomical visualization of the index ureter was assessed intraoperatively by the investigator as “yes” or “no” on the ability to visualize the ureter at each time point. Qualitative assessment of fluorescence intensity was performed using a Likert scale (0=none, 1=mild, 2=moderate, and 3=strong). Adverse events were recorded and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Causal relationships between AEs and pudexacianinium were determined as assessed by the investigator. Safety assessments also included clinical laboratory evaluations (hematology, serum chemistry, and urinalysis), 12-lead electrocardiogram, vital signs measurements, and physical examination. Change from baseline in QTcF was determined for each participant using the mean value of triplicate readings at each time point. For the first three participants, blood samples for PK assessments were collected prior to pudexacianinium administration, at 10, 30, and 60 min after administration, then every 30 min thereafter until a final collection was obtained at the end of surgery (or at 180 min if the surgery was completed in less than 105 min). For the subsequent nine patients enrolled after the protocol was amended, blood was collected prior to administration, then at 10 min and either 30 or 60 min after administration, and at the end of surgery (or at 180 min if the duration of surgery was less than 105 min). Total urine samples to assess the amount of pudexacianinium excreted in the urine were collected during surgery. Before protocol amendment, point urine samples for PK assessments were collected prior to pudexacianinium administration, at 10, 30, and 60 min after administration, then every 30 min thereafter until a final collection was obtained at the end of surgery. Urine sample collection at all time points was not feasible during certain portions of surgical procedures. After protocol amendment, point urine samples were collected pre-dose and at the end of surgery. Fluorescence intensity was qualitatively assessed as dye visibility by the investigator at each time point using the 4-point Likert scale. The duration of visualization of the index ureter(s) was based on the result of the first and the last positive visualized time point. Investigators were asked to assess the clinical benefit of visualization provided by pudexacianinium during surgery by answering “yes” or “no” to the following questions: Was the location of the index ureter(s) as expected? Did visualization of the index ureter(s) occur with white light at 30 min after pudexacianinium administration? Did visualization of the index ureter(s) occur with white light at the end of surgery? Was NIR-F superior to white light in terms of visualization of the index ureter(s)? Did the location of the ureter visualized by NIR-F alter the operative plan? Were any ureter anomalies or abnormalities observed? Was the location of the index ureter(s) as expected? Did visualization of the index ureter(s) occur with white light at 30 min after pudexacianinium administration? Did visualization of the index ureter(s) occur with white light at the end of surgery? Was NIR-F superior to white light in terms of visualization of the index ureter(s)? Did the location of the ureter visualized by NIR-F alter the operative plan? Were any ureter anomalies or abnormalities observed? The contralateral ureter was assessed using the same binary questions for anatomical visualization and Likert scale when feasible. A post hoc analysis (not protocol-specified) was conducted to quantitatively assess fluorescence intensity. Full color images of ureters taken during surgery were decomposed into red (R), green (G), and blue (B) components using ImageJ video analysis software ( https://imagej.nih.gov/ij/ ). As the fluorescence emitted by pudexacianinium is displayed as green in color in the surgical video, the color contrast between the dye fluorescence in the ureter and the surrounding tissues was quantified by calculating a ratio of the signal levels G/(R + B) where R, G, and B are the average values of the signal for each color. A commensurate ratio value was calculated for signals emanating from the tissues surrounding the ureter lumen. A comparison of these two ratio values was expressed as a “contrast enhancement factor” (CEF), where CEF = (G/(R + B) inside )/(G/(R + B) outside ), to quantify the color contrast that the surgeon observes when pudexacianinium is present in the ureter and is visualized with a Stryker camera and light source. A CEF value was calculated for the case when dye was present in the ureter (“dye”) and for the case when no dye was present (“without dye”). Fluorescence intensity was qualitatively assessed as dye visibility by the surgeon at each time point using the 4-point Likert scale. Sample size was selected to provide adequate information to determine the dose of pudexacianinium for ureter visualization and was not determined based on a statistical power calculation. Efficacy analyses were performed based on the full analysis set, defined as all participants who received pudexacianinium and had at least one ureter visualization assessment during surgery. Safety was evaluated for the safety analysis set, defined as all participants who received pudexacianinium. Pharmacokinetic assessments were performed on the PK analysis set, defined as all participants who received at least one dose of pudexacianinium and had at least one plasma or urine concentration data point available at the time of dosing and sampling. All data were summarized descriptively using mean, SD, minimum, median, and maximum for continuous variables, and frequency and percentage for categorical data. No hypothesis testing or statistical comparisons were performed.

Results of this phase 2, dose-ranging study show that IV administration of pudexacianinium leads to enhanced anatomical visualization of the ureter under NIR-F conditions at all doses. Sustained enhancement of ureter visualization was observed for five of the six patients who received the 1.0-mg dose and all three patients who received the 3.0-mg dose during surgery. According to the visualization data and PK findings, plasma pudexacianinium concentrations and urinary pudexacianinium excretion increase in a dose-dependent manner. Results of the quantitative assessment of color contrast showed that the CEF was notably less for the 0.3-mg dose than for the 1.0-mg or 3.0-mg dose of pudexacianinium, indicating that the higher doses provide greater assurance of enabling the surgeon to visualize the ureter consistently. Ureters were visualized at the end of surgery for all except two participants (one received the 0.3-mg dose and one received the 1.0-mg dose). It is important to note that BMI is an important factor to consider when assessing optical visualization of vessels beneath the tissue surface. In the current study, participants who received pudexacianinium 1.0 mg had higher mean and median BMIs than participants in the other dose cohorts. Pudexacianinium appeared to be safe and well tolerated in this study. One case of proteinuria grade 1 was considered related to pudexacianinium (1.0-mg dose) administration, and the few serious AEs that occurred were not related to pudexacianinium and consistent with the underlying indication of colorectal surgery. It is also important to note that no AEs observed were suggestive of hypersensitivity or anaphylactic reactions, which have been reported in isolated cases immediately following administration of high doses of ICG [ 16 – 19 ]. The root cause of these reactions on ICG is yet to be determined but may be related to the iodine component, which is not present in pudexacianinium. No hypersensitivity reactions were reported for any participants in the completed phase 1 trial [ 15 ], nor were any toxicity reactions observed at potential target doses in preclinical studies [ 14 ]. Any potential risk is further mitigated by the administration of pudexacianinium solely within the confines of a surgical suite/operating room, an environment well-equipped to monitor and treat hypersensitivity reactions in the unlikely event they might occur. Published rates of IUI varied by surgery type and may be higher than previously reported [ 3 ]. Image-guided surgery using NIR-F imaging is a promising technique that offers real-time visualization for surgeons, helping minimize the risk for IUI and potentially leading to better overall patient outcomes. Because no imaging agents are yet approved by the FDA for ureter visualization, current options are limited to off-label use of methylene blue and ICG, or stents, which have been associated with increased time in the operating room, medical costs, and potential for ureteral injury [ 8 , 9 ]. Results from the nonclinical pharmacology in vivo models, both in laparoscopic and open surgeries, were predictive of the enhanced ureter visualization observed in adult patients undergoing laparoscopic/minimally invasive colorectal surgery [ 14 ]. The 1.0-mg pudexacianinium dose provided visualization throughout the duration of surgery for five of the six participants. The surgeon survey on clinical benefit showed that benefits of visualization (6/6 questions) were apparent in all participants at the 1.0 mg and 3.0 mg doses. By comparison, the 0.3-mg dose provided reduced fluorescence intensity and shorter duration of visualization that was considered inadequate for intraoperative ureter visualization, while the 3.0-mg dose provided stronger fluorescence intensity over the 1.0-mg dose. Taken together with previous findings to date on pudexacianinium, we anticipate that this imaging agent will provide clinical benefit by addressing the unmet medical need for improved ureter identification using a safe, noninvasive, intraoperative visualization agent. Moreover, the benefits of avoiding intraoperative stents should minimize ureteral injuries and associated complications, potentially decrease operating times, avoid repeat surgeries, and reduce the possibility of increased medical costs from side effects. This study was limited by the small sample size with descriptive statistics used to evaluate differences between doses. Additionally, no participants with renal impairment were included in the study, so it remains to be determined whether slower renal elimination might impact fluorescence intensity and duration of ureter visualization. An investigation of the safety and tolerability and of the PK parameters of pudexacianinium in individuals with renal impairment is currently planned ( NCT05495581 ). In conclusion, this phase 2 study demonstrated that administration of the novel fluorescent imaging agent pudexacianinium, at doses of 1.0 mg and 3.0 mg, provides ureteral visualization for the full duration of minimally invasive, laparoscopic colorectal procedures. The CEF threshold of 1.5 for dye identification is relevant based on ureter identification and visualization that occurred at CEF values above the threshold. Both qualitatively and quantitatively, data indicated that there was a direct relationship between signal intensity and pudexacianinium dose. High proportions of patients in the 1.0-mg (89.7%) and 3.0-mg (95.2%) dose groups had CEF values above 1.5, with potential benefit of the 3.0-mg versus 1.0-mg dose based on the higher proportion of patients above the dye identification threshold. Pudexacianinium, across studies to date, has demonstrated a consistent and desirable safety, tolerability, and PK profile. In the current study, all doses of pudexacianinium were tolerable and had good safety profiles.

Below is the link to the electronic supplementary material. Supplementary file1 (MP4 27158 KB) Supplementary file2 (DOCX 39 KB) Supplementary file1 (MP4 27158 KB) Supplementary file2 (DOCX 39 KB)